||This article appears to be written like an advertisement. (March 2011)|
Anadis is a biotechnology company based in Melbourne, Australia that trades on the Australian Stock Exchange with the symbol IMC. an ADR Level I program was initiated in late 2007, and the company is quoted over the counter in the U.S. with the ticker ANDIY
The company focused on antigen-primed, dairy-derived health products. Anadis’ proprietary, technology enables it to rapidly develop polyclonal antibody and other proteins-based solutions to a range of important diseases. The all-natural bovine colostrum-derived platform, its regulatory classification as GRAS (Generally Regarded as Safe) when administered orally and the proprietary methods of manufacturing, allows for short time-frame from bench to market with high manufacturing scalability.
With expertise in research, commercialisation and manufacturing Anadis specialises in innovative nutraceutical, pharmaceutical and related therapeutic technology products, including Oral and GI Mucositis, Routine and Avian Influenza, - E. coli Travellers' diarrhoea (TD), Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), and Anthrax containment.
- [www.immuron.com.au Official website]
- "Anadis". Australian Stock Exchange. 2007-06-05.
|This biotechnology article is a stub. You can help Wikipedia by expanding it.|
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|